focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Share News (ONC)

Share Price Information for Oncimmune (ONC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.50
Bid: 22.20
Ask: 26.00
Change: 0.00 (0.00%)
Spread: 3.80 (17.117%)
Open: 24.50
High: 0.00
Low: 0.00
Prev. Close: 24.50
ONC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Elixirr meets guidance, in strong start to 2023

Mon, 27th Feb 2023 10:37

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Elixirr International PLC, up 20% at 503.0 pence, 12-month range 412p-780p. The consultancy firm says 2022 was a strong year, with all metrics to be "in line or above" market expectations. Revenue is expected to rise 40% to GBP70.7 million, within previous guidance, and adjusted earnings before interest, tax, depreciation and amortisation is expected at GBP20.4 million - which is in line with Elixirr's guidance of exceeding GBP20 million. Says 2023 has started "strongly" with an acceleration of organic growth in the first quarter, and January seeing record monthly revenue.

----------

Directa Plus PLC, up 10% at 87p, 12-month range 76p-87p. The graphene nanoplatelet products producer and supplier says revenue in 2022 is now expected at not less than EUR10.8 million, which is up from EUR10.0 million communicated back in December's trading update. This represents a 25% increase year-on-year. Says momentum has continued into 2023, with trading meeting market expectations, which Directa cites as revenue of EUR13.5 million for the year.

----------

AIM - LOSERS

----------

Hercules Site Services PLC, down 38% at 44.99p, 12-month range 40p-73p. The labour supply company for the UK infrastructure sector raises GBP1.7 million in a placing of 3.8 million shares at issue price of 45p - which represents a 24% discount to Friday's closing price of 59p. "With a strong 2023 pipeline in place, these funds will support further organic growth in our Labour Supply division, which represented over 67% of our revenue in 2022," says Chief Executive Brusk Korkmaz.

----------

Oncimmune Holdings PLC, down 23% at 42p, 12-month range 36.69p-146.0p. The immuno-diagnostics developer says, in the 15 months to August 31, revenue was GBP3.8 million, little changed from GBP3.7 million in the year to May 31. Pretax loss widens to GBP11.6 million from GBP6.1 million across the same time frame. However, says revenue in the first six months of financial 2023 are expected to exceed GBP3.8 million, and it expects to be operating cashflow positive during the year.

----------

Forward Partners Group PLC, down 6.5% at 36p, 12-month range 35p-98.4p. The early-stage technology-focused investor says the fair value of its portfolio fell 40% to no less than GBP79.0 million at December 31, from GBP117.1 million a year before. Net asset value per share is expected to plunge to 71.0p from 104p a year before. The investment firm blamed valuation headwinds, "due to public market and macroeconomic pressures". "Despite the pressure on valuations many of them still grew rapidly," says Chief Executive Nic Brisbourne.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
23 Jul 2021 12:46

Oncimmune signs agreement with major cancer centre to profile patients

Oncimmune signs agreement with major cancer centre to profile patients

Read more
23 Jul 2021 09:44

Oncimmune inks research deal with Dana-Farber Cancer Institute

(Sharecast News) - Immunodiagnostics group Oncimmune has signed an autoantibody profiling contract with Dana-Farber Cancer Institute, based in Boston, Massachusetts, it announced on Friday.

Read more
22 Jul 2021 19:40

TRADING UPDATES: Tekcapital investee and Puma VCT 13 raise funds

TRADING UPDATES: Tekcapital investee and Puma VCT 13 raise funds

Read more
8 Jun 2021 13:11

TRADING UPDATES: Nightcap toasts sales jump after May reopening

TRADING UPDATES: Nightcap toasts sales jump after May reopening

Read more
8 Jun 2021 10:57

Oncimmune FY revenues tracking in line with expectations

(Sharecast News) - Immunodiagnostics group Oncimmune said on Tuesday that 2021 full-year revenues were in line with market expectations,

Read more
1 Jun 2021 15:51

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
5 May 2021 19:20

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

Read more
6 Apr 2021 16:54

IN BRIEF: Oncimmune signs separate deals with Roche and Cedars-Sinai

IN BRIEF: Oncimmune signs separate deals with Roche and Cedars-Sinai

Read more
6 Apr 2021 09:14

Oncimmune secures contracts with Roche and Cedars-Sinai

(Sharecast News) - Immunodiagnostics group Oncimmune said on Tuesday that it had signed two separate agreements for the use of its newly developed and proprietary Infectious Disease panel with Roche Pharmaceuticals and Cedars-Sinai Medical Center.

Read more
25 Mar 2021 16:46

Oncimmune secures GBP9 million in oversubscribed share placing

Oncimmune secures GBP9 million in oversubscribed share placing

Read more
25 Mar 2021 11:28

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

AIM WINNERS & LOSERS: Tandem rises on strong results, positive outlook

Read more
15 Feb 2021 10:30

Oncimmune Interim Loss Narrows On Higher Revenue And Lower Costs

Oncimmune Interim Loss Narrows On Higher Revenue And Lower Costs

Read more
8 Feb 2021 16:09

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
19 Jan 2021 16:30

EXECUTIVE CHANGE SUMMARY: Next CEO Wolfson Joins Board Of Deliveroo

EXECUTIVE CHANGE SUMMARY: Next CEO Wolfson Joins Board Of Deliveroo

Read more
14 Jan 2021 14:55

DIRECTOR DEALINGS: Oncimmune Non-Exec Cheung To Sells 195,000 Shares

DIRECTOR DEALINGS: Oncimmune Non-Exec Cheung To Sells 195,000 Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.